A Phase 2 Randomized Double-Blind Placebo-Controlled Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adult Patients Previously Treated for CDI